SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding SELLAS Life Sciences Group, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 94 | 1 | 112 | +19 |
| Shares | 32.9M | 10.7K | 35.5M | +2.53M (+7.7%) |
| Value | $53.1M | $17.3K | $133.7M | +$80.7M (+152.2%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (28)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (9)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Anson Funds Management LP | 6,032,938 | $9.71M |
| Renaissance Technologies LLC | 291,822 | $469.8K |
| Citadel Advisors LLC | 194,357 | $312.9K |
| Prosperity Financial Group, Inc. | 18,500 | $29.8K |
| Quadrature Capital Ltd | 16,579 | $26.6K |
| Marshall Financial Group LLC | 10,309 | $16.6K |
| Brooklyn FI, LLC | 10,240 | $16.5K |
| Great Valley Advisor Group, Inc. | 10,000 | $16.0K |
| SRS Capital Advisors, Inc. | 540 | $869 |
Not filed for Q4 2025 yet (1)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| CIBC Bancorp USA Inc. | 10,736 | $17.3K |